Belantamab combinations for relapsed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at people with multiple myeloma who have already started a belantamab combination (BVd or BPd) through a compassionate use program. It aims to see how well these combinations work and how safe they are, so researchers can learn more about their benefits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma that has come back or stopped responding to treatment.
- You have already received at least one dose of a belantamab combination (called BVd or BPd) through a special compassionate use program.
- You were 18 years or older when you started that belantamab combination.
- You started the belantamab combination as treatment for your first or second relapse (not later than that).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether belantamab mafodotin combined with carfilzomib, pomalidomide, and dexamethasone can better treat multiple myeloma that has come back. It may help people who have already tried other myeloma treatments but whose cancer has progressed again.
This trial tests two new medicines, talquetamab and belantamab mafodotin, for people whose multiple myeloma has come back or stopped responding to earlier treatments. The goal is to see if this combination can shrink the cancer and help you feel better.
This trial tests a new way of giving a combination of three drugs—belantamab mafodotin, bortezomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if a different dosing schedule is more effective and safer.
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
This program provides access to a new drug called belantamab mafodotin, which is being combined with other medicines for people with multiple myeloma who have run out of standard options. The goal is to see if the combination can help control the disease.
This study tests the safety and effectiveness of the drug belantamab, alone or with other treatments, for people with multiple myeloma that has come back or stopped responding to previous treatments.
Hear when a new Relapse Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.